December 26, 2014 11:12 AM ET

Biotechnology

Company Overview of InteKrin Therapeutics Inc.

Company Overview

InteKrin Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapeutics for inflammatory and metabolic disorders. Its product includes INT-131, a peroxisome proliferator-activated receptor gamma modulator that targets inflammation and activates neuroprotective pathways. The company was founded in 2005 and is based in Redwood City, California. As of February 24, 2014, InteKrin Therapeutics Inc. operates as a subsidiary of Coherus Biosciences Inc.

201 Redwood Shores Parkway

Suite 200

Redwood City, CA 94065

United States

Founded in 2005

Phone:

650-941-5501

Fax:

650-941-5501

Key Executives for InteKrin Therapeutics Inc.

Founder and Director
Age: 59
Chief Scientific Officer and Chief Medical Officer
Director of Russia Development
Compensation as of Fiscal Year 2014.

Similar Private Companies By Industry

Company Name Region
Anagen Therapeutics, Inc. United States
Polymerix Corporation United States
Biotage, LLC United States
PharmaGenoma, Inc. United States
Oligos Etc., Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
February 24, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact InteKrin Therapeutics Inc., please visit www.intekrin.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.